Gujarat Themis Biosyn growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
+10.0%
+9.7%
−1.4%
−4.3%
−4.5%
+67.1%
+15.9%
−46.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GUJTHEM₹375.80

Gujarat Themis Biosyn Limited

· Pharma & Health
₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹4,095 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.0—
EBITDA Growth—+9.7—
EBIT Growth—-1.4—
Net Income Growth—-4.3—
EPS Growth—-4.5—
Total Assets Growth—+67.1—
Total Equity Growth—+15.9—
Cash from Operations Growth—-46.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.